Olfa Derbel

701 total citations
24 papers, 403 citations indexed

About

Olfa Derbel is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Olfa Derbel has authored 24 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in Olfa Derbel's work include Sarcoma Diagnosis and Treatment (7 papers), Ovarian cancer diagnosis and treatment (5 papers) and BRCA gene mutations in cancer (4 papers). Olfa Derbel is often cited by papers focused on Sarcoma Diagnosis and Treatment (7 papers), Ovarian cancer diagnosis and treatment (5 papers) and BRCA gene mutations in cancer (4 papers). Olfa Derbel collaborates with scholars based in France, Switzerland and Spain. Olfa Derbel's co-authors include Jean‐Yves Blay, Philippe A. Cassier, Anne‐Valérie Decouvelaere, Pierre Méeus, Christelle de la Fouchardière, Isabelle Ray‐Coquard, Gualter Vaz, Isabelle Ray‐Coquard, Jean‐Louis Peix and Céline Ségura‐Ferlay and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Olfa Derbel

23 papers receiving 396 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Olfa Derbel France	10	211	209	107	73	72	24	403
Juan Varela-Durán Spain	11	268 1.3×	183 0.9×	211 2.0×	91 1.2×	36 0.5×	22	541
Rashpal Flora United Kingdom	9	184 0.9×	176 0.8×	95 0.9×	112 1.5×	34 0.5×	17	468
Martin Granados‐García Mexico	11	135 0.6×	126 0.6×	76 0.7×	253 3.5×	145 2.0×	44	550
Jean Jacques Michels France	7	195 0.9×	152 0.7×	64 0.6×	81 1.1×	99 1.4×	11	346
J. F. Graadt van Roggen Netherlands	11	318 1.5×	95 0.5×	195 1.8×	322 4.4×	37 0.5×	14	631
Nicole D. Riddle United States	11	126 0.6×	80 0.4×	138 1.3×	69 0.9×	22 0.3×	33	295
Rasheed Hammadeh United States	9	156 0.7×	55 0.3×	54 0.5×	122 1.7×	41 0.6×	17	297
Loïc Lebellec France	9	186 0.9×	98 0.5×	137 1.3×	55 0.8×	29 0.4×	22	303
Deepak M. Parikh India	9	101 0.5×	102 0.5×	69 0.6×	126 1.7×	83 1.2×	18	335
A Ayadi‐Kaddour Tunisia	9	180 0.9×	78 0.4×	93 0.9×	132 1.8×	11 0.2×	72	352

Countries citing papers authored by Olfa Derbel

Since Specialization

Citations

This map shows the geographic impact of Olfa Derbel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olfa Derbel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olfa Derbel more than expected).

Fields of papers citing papers by Olfa Derbel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olfa Derbel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olfa Derbel. The network helps show where Olfa Derbel may publish in the future.

Co-authorship network of co-authors of Olfa Derbel

This figure shows the co-authorship network connecting the top 25 collaborators of Olfa Derbel. A scholar is included among the top collaborators of Olfa Derbel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olfa Derbel. Olfa Derbel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guiu, Séverine, Judith Balmañà, Pablo Lemercier, et al.. (2024). 179O Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER-positive, HER2-negative breast cancer harboring homologous recombination repair (HRR) deficiency or microsatellite instability (MSI): Results of the international phase II DOLAF trial. ESMO Open. 9. 103201–103201. 3 indexed citations

Méry, Benoîte, Christine Ménétrier‐Caux, Pierre-Étienne Heudel, et al.. (2023). Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study. Breast Cancer Targets and Therapy. Volume 15. 311–325. 4 indexed citations

Bidard, François‐Clément, Florence Dalenc, Thibault De La Motte Rouge, et al.. (2021). Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial.. Journal of Clinical Oncology. 39(15_suppl). 1070–1070. 1 indexed citations

Labidi‐Galy, Sana Intidhar, Thibault De La Motte Rouge, Olfa Derbel, et al.. (2018). Predictive factors for prolonged response to olaparib as maintenance therapy in ovarian cancer patients with BRCA mutations.. Journal of Clinical Oncology. 36(15_suppl). 5558–5558. 2 indexed citations

Labidi‐Galy, Sana Intidhar, Timothée Olivier, Manuel Rodrigues, et al.. (2017). Location of mutation in BRCA2 gene and survival in patients with ovarian cancer. Annals of Oncology. 28. v335–v335. 6 indexed citations

Derbel, Olfa, Pierre-Étienne Heudel, Claire Cropet, et al.. (2017). Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort). PLoS ONE. 12(2). e0158406–e0158406. 56 indexed citations

Ray‐Coquard, Isabelle, Véronique Corset, Christian Baudet, et al.. (2017). Actionable molecular alterations in advanced gynecologic malignancies: First results from the ProfiLER program (NCT01774409) in France. Annals of Oncology. 28. v333–v333. 1 indexed citations

Penault–Llorca, F, Jean‐Christophe Grenier, Marianne Leheurteur, et al.. (2017). Abstract P2-05-10: UCBG 2-14: A prospective multicenter non-randomized trial evaluating the effect of EndoPredict® (EPclin®) clinico-genomic test on treatment decision making among patients with intermediate clinical risk. Cancer Research. 77(4_Supplement). P2–5. 2 indexed citations

Decouvelaere, Anne‐Valérie, et al.. (2015). Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma. PubMed. 5(1). 12–12. 39 indexed citations

10.

Fouchardière, Christelle de la, Olfa Derbel, Myriam Decaussin‐Petrucci, et al.. (2015). Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study. Targeted Oncology. 11(1). 71–82. 10 indexed citations

11.

Derbel, Olfa, Pierre-Étienne Heudel, Claire Cropet, et al.. (2014). Improved survival in an exhaustive population based on a cohort of liposarcoma (LPS) patients treated in expert centers according to clinical practice guidelines (CPG'S): Experience from Rhone Alpes (RA) region.. Journal of Clinical Oncology. 32(15_suppl). 10581–10581.

12.

Derbel, Olfa, Pierre Méeus, Dominique Ranchère, et al.. (2013). Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience. BMC Cancer. 13(1). 109–109. 52 indexed citations

13.

Blay, Jean‐Yves, Antoîne Italiano, Isabelle Ray‐Coquard, et al.. (2013). Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. BMC Cancer. 13(1). 64–64. 60 indexed citations

14.

Derbel, Olfa, Qing Wang, Françoise Desseigne, et al.. (2013). Impact of KRAS, BRAF and PI3KCA mutations in rectal carcinomas treated with neoadjuvant radiochemotherapy and surgery. BMC Cancer. 13(1). 200–200. 22 indexed citations

15.

Blay, Jean‐Yves, Olfa Derbel, & Isabelle Ray‐Coquard. (2013). The clinician’s perspective on sarcoma pathology reporting: impact on treatment decisions?. Pathology. 46(2). 121–125. 4 indexed citations

16.

Blay, Jean‐Yves, Olfa Derbel, & Isabelle Ray‐Coquard. (2013). Do Our Current Clinical Trial Designs Help to Guide Clinical Practice?. American Society of Clinical Oncology Educational Book. 33. e381–e385. 1 indexed citations

17.

Dufresne, Armelle, Olfa Derbel, Philippe A. Cassier, et al.. (2012). Giant-cell tumor of bone, anti-RANKL therapy. BoneKEy Reports. 1. 149–149. 29 indexed citations

18.

Derbel, Olfa, Claire Cropet, Pierre Méeus, et al.. (2012). Adhesion to Clinical Practices Guidelines (CPG'S) and Role on Survival for Soft Tissue Sarcoma Patients. Analysis of a Population Based Cohort from Rhone-Alpes Region. Annals of Oncology. 23. ix478–ix478. 9 indexed citations

19.

Derbel, Olfa, Céline Ségura‐Ferlay, Jean‐Christophe Lifante, et al.. (2011). Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer. 11(1). 469–469. 66 indexed citations

20.

Benoit, Amandine, et al.. (2011). Unusual Adverse Event With Vandetanib in Metastatic Medullary Thyroid Cancer. Journal of Clinical Oncology. 30(2). e21–e23. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact